Technology | March 28, 2014

VeriTeQ’s radiation dosimetry products already have six FDA clearances and CE approvals

Q Inside SmartMarker Vertiq Corp. Radiation Dose Management Radiation Therapy

March 28, 2014 — VeriTeQ Corp. is rebranding its Q Inside SmartMarker to lead its radiation dosimetry business. Q Inside SmartMarker (previously known as DVS SmartMarker) is the only U.S. Food and Drug Administration (FDA)-cleared implantable radio frequency (RF) radiation sensor that provides localization of a tumor and measures radiation dose at the tumor site. VeriTeQ’s radiation dosimetry products have six FDA clearances and CE approvals, and the company has more than 100 patents, patents pending and exclusive licenses.

Q Inside SmartMarker is an FDA-cleared, implantable radiation sensor for use in breast and prostate cancer patients undergoing photon external beam treatments. It is implanted in, or adjacent to, solid-mass tumors and gathers data on the actual dose of radiation being delivered to the tumor and surrounding normal tissue. Q Inside SmartMarker is intended to be used in the balancing between delivering maximum dose to the tumor while minimizing the impact to healthy tissue. The sensor can confirm the treatment is conforming to the physician’s plan, as even a small deviation from planned dose can have a significant impact on patient survival rates.

Scott R. Silverman, chairman and CEO of VeriTeQ, stated, “Radiation under-dosing and, perhaps more importantly, radiation overdosing have been a top concern of the medical community for years. Confirming the delivered dose of radiation is known to have a direct and significant impact on treatment efficacy and patient survival rates, and our Q Inside SmartMarker can support healthcare providers with this potentially life-saving data.”

According to the ECRI Institute, radiation or computed tomography (CT) overdose make the list of the Top 10 Technology Hazards each year going back at least eight years. These hazards include radiation overdose and other errors during radiation therapy; unnecessary exposures and radiation burns from diagnostic radiology procedures; and exposure hazards from radiation therapy and CT.

Q Inside SmartMarker is compatible with a variety of commercially available systems including, but not limited to, CyberKnife System, Varian kV Trilogy System, TomoTherapy, Siemens MV CBCT and Resonant Medical.

For more information: www.veriteqcorp.com


Related Content

News | Radiation Oncology

May 2, 2025 — GE HealthCare has announced an intended expansion of its radiation oncology portfolio as well as the ...

Time May 03, 2025
arrow
News | Radiology Education

April 21, 2025 — On June 20, the American Society of Radiologic Technologists (ASRT) will award Life Member status to ...

Time April 21, 2025
arrow
News | Radiology Business

April 16, 2025 — According to a new report, the U.S. Radiotherapy Market is projected to reach $2.49 billion by 2030 ...

Time April 17, 2025
arrow
News | ASTRO

March 14, 2025 — Another pivotal milestone in the nation’s fight against cancer recently took place with the ...

Time March 17, 2025
arrow
News | Computed Tomography (CT)

Royal Philips recently received 510(k) clearance from the US Food and Drug Administration (FDA) for its detector-based ...

Time November 13, 2024
arrow
News | Computed Tomography (CT)

At the annual AHRA (American Healthcare Radiology Administrators) conference in Orlando, Florida, Bayer announced an ...

Time August 09, 2024
arrow
News

Aug. 5, 2024 — Researchers from The University of Texas MD Anderson Cancer Center have demonstrated that adding ...

Time August 09, 2024
arrow
News | PET-CT

July 31, 2024 — In a head-to-head comparison with FDG PET/CT, FDG PET/MRI demonstrated comparable or superior diagnostic ...

Time July 31, 2024
arrow
Feature | Radiation Oncology | By Christine Book

News emerging from several leading organizations and vendors in the radiation therapy arena came in at a fast pace in ...

Time July 30, 2024
arrow
News | Radiation Oncology

July 11, 2024 — The American Society for Radiation Oncology (ASTRO) issued the following statement from Jeff M ...

Time July 11, 2024
arrow
Subscribe Now